

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1.-23. (Cancelled)

24. (Currently Amended) A kit for amplifying sequences of the cystic fibrosis CTFR gene comprising one or more pairs of nucleic acid primers ~~selected from the group consisting of~~ including:

~~5'-GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG-3' (SEQ ID NO: 3) and~~
~~5'-GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC-3' (SEQ ID NO: 4), 5'-~~
~~GCGGTCCCAAAAGGGTCAGTGAATCATTCAAGTGGGTATAAGCAG-3' (SEQ ID NO: 5)~~
~~and 5'-GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC-3' (SEQ ID NO: 6),~~
~~5'-GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC-3' (SEQ ID NO: 7)~~
~~and 5'-GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGTGT-3' (SEQ ID~~
~~NO: 8), 5'-GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA-3' (SEQ ID~~
~~NO: 9) and 5'-GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT-3' (SEQ ID~~
~~NO: 10), 5'-GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT-3' (SEQ ID~~
~~NO: 11) and 5'-GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG-3'~~
~~(SEQ ID NO: 12), 5'-GCGGTCCCAAAAGGGTCAGTGAAAGTATTTATTTTCTGGAAC~~
~~-3' (SEQ ID NO: 13) and 5'-~~
~~GCGGTCCCAAAAGGGTCAGTGTGTGTAGAATGATGTCAGCTAT-3' (SEQ ID NO: 14),~~
~~5'-GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG-3' (SEQ ID NO:~~
~~15) and 5'-GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA-3' (SEQ ID~~
~~NO: 16), 5'-GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA-3' (SEQ ID~~
~~NO: 17) and 5'-GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT-3' (SEQ ID~~
~~NO: 18), 5'-GCGGTCCCAAAAGGGTCAGTGGTCCCCTTTTATTCTTTTGC-3' (SEQ~~
~~ID NO: 19) and 5'-GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG-3'~~
~~(SEQ ID NO: 20), 5'-GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC-3'~~
~~(SEQ ID NO: 21) and 5'-GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG~~

~~3' (SEQ ID NO: 22), 5' GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG-~~
~~3' (SEQ ID NO: 23) and 5' GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA~~
~~3' (SEQ ID NO: 24), 5' GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC 3'~~
~~(SEQ ID NO: 25) and 5' GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC 3'~~
~~(SEQ ID NO: 26), 5' GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG 3'~~
~~(SEQ ID NO: 27) and 5' GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC 3'~~
~~(SEQ ID NO: 28), 5' GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC 3' (SEQ~~
~~ID NO: 29) and 5' GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG 3'~~
~~(SEQ ID NO: 30), and 5'~~
~~GCGGTCCCAAAAGGGTCAGTAAGTATTGGACAACTTGTTAGTCTC 3' (SEQ ID NO:~~
~~31) and 5' GCGGTCCCAAAAGGGTCAGTCGCCTTTCAGTTGTATAATTT 3' (SEQ ID~~
~~NO: 32),~~

in an amount sufficient to perform a polymerase chain reaction amplification of a nucleic acid sample.

25. (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is five pairs of nucleic acid primers ~~and said five pairs of primers include SEQ ID NOs: 13 and 14.~~

26. (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is ten pairs of nucleic acid primers ~~and said ten pairs of primers include SEQ ID NOs: 13 and 14.~~

27. (Currently Amended) The kit of claim 24, wherein said one or more pairs of nucleic acid primers is fifteen pairs of nucleic acid primers ~~and said fifteen pairs of primers include SEQ ID NOs: 13 and 14.~~

28. (New) The kit of claim 24, further comprising one or more pairs of nucleic acid primers selected from the group consisting of:

5'- GCGGTCCCAAAAGGGTCAGTTGTAGGAAGTCACCAAAG -3' (SEQ ID NO: 3) and
 5'- GCGGTCCCAAAAGGGTCAGTCGATACAGAATATATGTGCC -3' (SEQ ID NO: 4), 5'-
 GCGGTCCCAAAAGGGTCAGTGAATCATTCAAGTGGGTATAAGCAG -3' (SEQ ID NO: 5)
 and 5'- GCGGTCCCAAAAGGGTCAGTCTTCAATGCACCTCCTCCC -3' (SEQ ID NO: 6),
 5'- GCGGTCCCAAAAGGGTCAGTAGATACTTCAATAGCTCAGCC -3' (SEQ ID NO: 7)
 and 5'- GCGGTCCCAAAAGGGTCAGTGGTACATTACCTGTATTTTGT -3' (SEQ ID
 NO: 8), 5'- GCGGTCCCAAAAGGGTCAGTGTGAATCGATGTGGTGACCA -3' (SEQ ID
 NO: 9) and 5'- GCGGTCCCAAAAGGGTCAGTCTGGTTTAGCATGAGGCGGT -3' (SEQ ID
 NO: 10), 5'- GCGGTCCCAAAAGGGTCAGTTTGGTTGTGCTGTGGCTCCT -3' (SEQ ID
 NO: 11) and 5'- GCGGTCCCAAAAGGGTCAGTACAATACATACAAACATAGTGG -3'
 (SEQ ID NO: 12), 5'- GCGGTCCCAAAAGGGTCAGTCAGATTGAGCATACTAAAAGTG -
 3' (SEQ ID NO: 15) and 5'-
 GCGGTCCCAAAAGGGTCAGTTACATGAATGACATTTACAGCA -3' (SEQ ID NO: 16),
 5'- GCGGTCCCAAAAGGGTCAGTAAGAACTGGATCAGGGAAGA -3' (SEQ ID NO: 17)
 and 5'- GCGGTCCCAAAAGGGTCAGTTCCTTTTGCTCACCTGTGGT -3' (SEQ ID NO: 18),
 5'- GCGGTCCCAAAAGGGTCAGTGGTCCCCTTTTATTCTTTTGC -3' (SEQ ID NO: 19)
 and 5'- GCGGTCCCAAAAGGGTCAGTTGGTTTCTTAGTGTTTGGAGTTG -3' (SEQ ID
 NO: 20), 5'- GCGGTCCCAAAAGGGTCAGTTGGATCATGGGCCATGTGC -3' (SEQ ID
 NO: 21) and 5'- GCGGTCCCAAAAGGGTCAGTACTACCTTGCCTGCTCCAGTGG -3'
 (SEQ ID NO: 22), 5'- GCGGTCCCAAAAGGGTCAGTAGGTAGCAGCTATTTTTATGG -3'
 (SEQ ID NO: 23) and 5'- GCGGTCCCAAAAGGGTCAGTTAAGGGAGTCTTTTGCACAA -3'
 (SEQ ID NO: 24), 5'- GCGGTCCCAAAAGGGTCAGTGCAATTTTGGATGACCTTC -3'
 (SEQ ID NO: 25) and 5'- GCGGTCCCAAAAGGGTCAGTTAGACAGGACTTCAACCCTC -3'
 (SEQ ID NO: 26), 5'- GCGGTCCCAAAAGGGTCAGTGGTGATTATGGGAGAACTGG -3'
 (SEQ ID NO: 27) and 5'- GCGGTCCCAAAAGGGTCAGTATGCTTTGATGACGCTTC -3'
 (SEQ ID NO: 28), 5'- GCGGTCCCAAAAGGGTCAGTTTCATTGAAAAGCCCGAC -3' (SEQ
 ID NO: 29) and 5'- GCGGTCCCAAAAGGGTCAGTCACCTTCTGTGTATTTTGCTG -3'
 (SEQ ID NO: 30), and 5'-

GCGGTCCCAAAGGGTCAGTAAGTATTGGACAACCTTGTTAGTCTC -3' (SEQ ID NO: 31) and 5'- GCGGTCCCAAAGGGTCAGTCGCCTTTCCAGTTGTATAATTT -3' (SEQ ID NO: 32).